These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31159813)
1. High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting. Han Q; Fan X; Wang X; Wang Y; Deng H; Zhang X; Zhang K; Li N; Liu Z Virol J; 2019 Jun; 16(1):74. PubMed ID: 31159813 [TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283 [TBL] [Abstract][Full Text] [Related]
3. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study. Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800 [TBL] [Abstract][Full Text] [Related]
4. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar. Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344 [TBL] [Abstract][Full Text] [Related]
5. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444 [TBL] [Abstract][Full Text] [Related]
6. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital. Del Rio-Valencia JC; Asensi-Diez R; Madera-Pajin R; Yunquera-Romero L; Muñoz-Castillo I Rev Esp Quimioter; 2018 Feb; 31(1):35-42. PubMed ID: 29376623 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Mushtaq S; Akhter TS; Khan A; Sohail A; Khan A; Manzoor S Front Pharmacol; 2020; 11():550205. PubMed ID: 32982753 [TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016 [TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973 [TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115 [TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng PN; Chiu YC; Chien SC; Chiu HC J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study. Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS Elife; 2023 Jan; 12():. PubMed ID: 36622106 [TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection. Mei YY; Chen YM; Wu YK; Zhang XH; Xu WX Can J Gastroenterol Hepatol; 2020; 2020():8872120. PubMed ID: 33194875 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356 [TBL] [Abstract][Full Text] [Related]
19. [A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China]. Qiu LX; Yu HB; Lin W; Liu YR; Qiu YD; Hu ZJ; Pang XH; Zhang J; Liu YL Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):395-401. PubMed ID: 35545564 [No Abstract] [Full Text] [Related]
20. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. Tsai WL; Wang CF; Cheng JS; Chen WC; Bair MJ; Lo CC PLoS One; 2020; 15(1):e0227424. PubMed ID: 31923251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]